Human Uncharacterized protein C9orf72(C9orf72) ELISA kit

Code CSB-EL004345HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
chromosome 9 open reading frame 72
Alternative Names
ALSFTD ELISA Kit; C9orf72 ELISA Kit; chromosome 9 open reading frame 72 ELISA Kit; CI072_HUMAN ELISA Kit; FTDALS ELISA Kit; MGC23980 ELISA Kit; Protein C9orf72 ELISA Kit; RP11-27J8.2 ELISA Kit; Uncharacterized protein C9orf72 ELISA Kit
Abbreviation
C9orf72
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
31.25 pg/mL-2000 pg/mL
Sensitivity
7.8 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Neuroscience
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human C9orf72 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %88
Range %84-92
1:2Average %100
Range %95-105
1:4Average %87
Range %83-91
1:8Average %104
Range %100-108
Recovery
The recovery of human C9orf72 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 8683-89
EDTA plasma (n=4)9189-95
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
20002.277 2.398 2.338 2.231
10001.947 1.930 1.939 1.832
5001.393 1.375 1.384 1.277
2500.911 0.935 0.923 0.816
1250.605 0.641 0.623 0.516
62.50.401 0.432 0.417 0.310
31.250.288 0.298 0.293 0.186
00.106 0.108 0.107
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human C9orf72 ELISA Kit was designed for the quantitative measurement of Human C9orf72 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 31.25 pg/mL-2000 pg/mL and the sensitivity is 7.8 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Component of the C9orf72-SMCR8 complex, a complex that has guanine nucleotide exchange factor (GEF) activity and regulates autophagy. In the complex, C9orf72 and SMCR8 probably constitute the catalytic subunits that promote the exchange of GDP to GTP, converting inactive GDP-bound RAB8A and RAB39B into their active GTP-bound form, thereby promoting autophagosome maturation. The C9orf72-SMCR8 complex also acts as a regulator of autophagy initiation by interacting with the ATG1/ULK1 kinase complex and modulating its protein kinase activity. Positively regulates initiation of autophagy by regulating the RAB1A-dependent trafficking of the ATG1/ULK1 kinase complex to the phagophore which leads to autophagosome formation. Acts as a regulator of mTORC1 signaling by promoting phosphorylation of mTORC1 substrates. Plays a role in endosomal trafficking. May be involved in regulating the maturation of phagosomes to lysosomes. Regulates actin dynamics in motor neurons by inhibiting the GTP-binding activity of ARF6, leading to ARF6 inactivation. This reduces the activity of the LIMK1 and LIMK2 kinases which are responsible for phosphorylation and inactivation of cofilin, leading to cofilin activation. Positively regulates axon extension and axon growth cone size in spinal motor neurons. Plays a role within the hematopoietic system in restricting inflammation and the development of autoimmunity.; Regulates stress granule assembly in response to cellular stress.; Does not play a role in regulation of stress granule assembly in response to cellular stress.
Gene References into Functions
  1. Review: Drosophila has been widely used to model G4C2 repeat RNA and dipeptide repeat protein toxicity. Overexpression of disease molecules in flies has revealed important molecular insights. These have been validated and further explored in human neurons differentiated from induced pluripotent stem cells (iPSCs), a disease-relevant model in which expanded G4C2 repeats are expressed in their native molecular context. PMID: 29729808
  2. Amyotrophic lateral sclerosis patients with C9ORF72 repeat expansions accumulate symmetric arginine demethylated proteins which co-localize with p62. PMID: 30022074
  3. This study demonstrated that C9orf72 RE is not genetically associated to MS spectrum. PMID: 30099204
  4. Results found that in sodium or potassium salt solutions, single-stranded d(C2G4)n within C9orf72 gene fold to form G-quadruplexes. Especially under slightly acidic conditions, d(C2G4)n oligonucleotides fold to form a distinctive higher order structure whose most striking feature is an "inverted" circular dichroism spectrum, which is distinguishable from the spectrum of the left handed DNA double-helix, Z-DNA. PMID: 29912891
  5. repeat RNA-sequestration of SRSF1 triggers the NXF1-dependent nuclear export of C9ORF72 transcripts retaining expanded hexanucleotide repeats PMID: 28677678
  6. Review discussing the discovery of an intronic (G4C2)*(G2C4) expansion causing the most common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This discovery linked ALS with a clinically distinct form of dementia and a larger group of microsatellite repeat diseases, and catalyzed basic and translational research. PMID: 29703376
  7. G4C2 hexanucleotide repeat expansions in the C9orf72 gene seem to be the cause of numerous cases of amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD). PMID: 29449030
  8. C9orf72 hexanucleotide repeat expansion (RE) mutation in amyotrophic lateral sclerosis (ALS) patients of 2 distinct origins, Ashkenazi and North Africa Jews. PMID: 29352617
  9. C9orf72 disease is clinically heterogeneous and without evident imaging markers PMID: 29441485
  10. that the overall frequency of C9orf72-positive cases in Greek FTD is high, comparable to Greek ALS, similar to some Western European, but significantly higher than some Mediterranean FTD populations PMID: 29166782
  11. The C9orf72 repeat expansion linked to aggressive disease in male patients with spinal-onset ALS. PMID: 27739539
  12. The genetic mutations of C9ORF72 caused amyotrophic lateral sclerosis. PMID: 29478603
  13. Findings provide evidence that C9orf72 poly GA is a key mediator of cytotoxicity and that cross-talk between DPR proteins likely modifies their pathogenic status in C9ALS/FTD. PMID: 28973350
  14. DNA methylation analysis of C9orf72 patients revealed that increased DNAm age-acceleration is associated with a more severe disease phenotype with a shorter disease duration and earlier age of onset. PMID: 28439722
  15. This study demonstrated that poly-GA triggers behavioral deficits through inflammation and protein sequestration that likely contribute to the prodromal symptoms and disease progression of C9orf72 patients. PMID: 28409281
  16. A pathological repeat expansion in the C9orf72 gene (50 repeats) was found in a patient with mild diffuse brain atrophy and type 2 progressive apraxia of speech. This is the first described association of this gene with type 2 progressive speech apraxia. PMID: 27166164
  17. The association of the C9orf72 repeat expansion with ALS and frontotemporal degeneration. PMID: 27713094
  18. in common neurological diseases, intermediate C9orf72 repeats do not influence disease risk but may associate with higher frequency of neuropsychiatric symptoms PMID: 28689190
  19. Mutations in the footprinted region of Nup54 polymers blocked both polymerization and binding by the toxic proline:arginine poly-dipeptide suggesting that toxicity of the C9orf72 PRn poly-dipeptide results in part from its ability to lock the FG repeats of nuclear pore proteins in the polymerized state. PMID: 28069952
  20. DPR-mediated dysfunction of U2 snRNP could account for as much as approximately 44% of the mis-spliced cassette exons in C9ORF72 patient brains. PMID: 28614712
  21. C9ORF72 repeat expansion leads to the upregulation of GluA1 in motor neurons, that could lead to a potential pathogenic excitotoxic mechanism in amyotrophic lateral sclerosis patients. PMID: 29367641
  22. This study demonstrated that in ALS with cognition disorder has C9orf72 mutation. PMID: 28444446
  23. von Economo neuron density was reduced in sporadic behavioral variant frontotemporal dementia (bvFTD) cases only. Thalamus degeneration was identified only in bvFTD cases with the C9ORF72 repeat expansion, and to a similar extent in cases with and without psychosis. No significant difference in von Economo neuron density or thalamus degeneration was seen between bvFTD cases with or without the C9ORF72 repeat expansion. PMID: 28482638
  24. The result of this study concluded that behavioral variant frontotemporal dementia patients carrying the C9ORF72 expansion may display more pronounced executive deficits together with less severe verbal memory impairment as compared to their non-carrier behavioral variant frontotemporal dementia counterparts. PMID: 28453474
  25. The C9orf72 hexanucleotide repeat was only found in humans, chimpanzees and gorillas, species with higher opposability indices PMID: 28010125
  26. the presence of an HREM was found to be coupled to a lower age of onset and a shorter disease survival in amyotrophic lateral sclerosis PMID: 27936955
  27. toxic poly-dipeptides translated from C9orf72 may account for hereditary cases of amyotrophic lateral sclerosis and frontotemporal dementia PMID: 29045370
  28. For DNA, the data are consistent with TMPyP4 stacking on the terminal tetrads and intercalation. For RNA, the thermodynamics of the two binding modes are consistent with groove binding and intercalation. PMID: 29274339
  29. Demyelinating lesions might facilitate expressivity of C9orf72 expansion, through NF-kappaB activation. This plausible association may lead to the identification of a therapeutic target in this subgroup of C9orf72-amyotrophic lateral sclerosis patients. PMID: 29055436
  30. These findings suggest that the presence of a C9orf72 mutation does not influence the tau signature of ALS or ALSci. PMID: 28562075
  31. We created Smcr8 knockout mice and found that Smcr8 mutant cells exhibit impaired autophagy induction, which is similarly observed in C9orf72 knockdown cells. Mechanistically, SMCR8/C9ORF72 interacts with the key autophagy initiation ULK1 complex and regulates expression and activity of ULK1 PMID: 27617292
  32. Our study did not find any pathological C9ORF72 repeat expansions in two large groups of patients with disease and multiple system atrophy, suggesting that C9ORF72 expansions do not play a major role in the susceptibility to the wider spectrum of Parkinsonism. However, study identified a statistically significant association between number of repeats and age at onset in Parkinson's disease patients. PMID: 27473499
  33. Pathogenesis may occur either due to loss of function of the C9orf72 gene, or a toxic gain of function, via the production of repetitive sense and antisense RNA and/or repetitive dipeptide repeat proteins. Recently, mouse knockouts have suggested that a loss of function of C9orf72 alone is insufficient to lead to neurodegeneration, whilst overexpression of hexanucleotide DNA is sufficient in a wide range of model systems PMID: 28364657
  34. We review what has been published regarding C9orf72 repeat size as modifier for phenotypic characteristics. Conclusive evidence is lacking, partly due to the difficulties in accurately defining the exact repeat size and the presence of repeat variability due to somatic mosaicism PMID: 28319737
  35. C9orf72 patients had enhanced visual network functional connectivity versus sporadic-motor and sporadic-early cases PMID: 28666709
  36. C9orf72 and ATXN2 repeat expansions cause ataxia, dementia, and parkinsonism in a Guyana family. PMID: 28124431
  37. These findings indicate that tracking poly(GP) proteins in Cerebrospinal fluid could provide a means to assess target engagement of G4C2 repeat expansion RNA-based therapies in symptomatic C9ORF72 repeat expansion carriers. PMID: 28356511
  38. Several family members of the patient suffered of atypical Parkinsonism, lateral amyotrophic sclerosis and dementia. We identified an abnormal hexanucleotide expansion in the C9orf72 gene in the proband. PMID: 29182198
  39. This study is an extensive characterization of induced pluripotent stem cells-derived motor neurons as cellular models of amyotrophic lateral sclerosis carrying C9orf72 hexanucleotide repeats. PMID: 27097283
  40. this implies that the difference between C9 hESCs and iPSCs may be crucial for investigating the neural phenotype of the C9/ALS-FTD disease, given that mutant hESCs are likely to present a more accurate and more severe phenotype than comparable iPSCs. PMID: 27773700
  41. The low penetrance of C9orf72 mutations, its contribution to sporadic cases, and its combination with other genes support an oligogenic model where two or more genes contribute to disease risk, onset, progression and phenotype: from 'pure' Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)to combined ALS/FTD PMID: 28087719
  42. Together, these data implicate C9ORF72 GGGGCC expansion-mediated sequestration of hnRNP H as a significant contributor to neurodegeneration in C9 amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. PMID: 27623008
  43. The chromosome 9 open reading frame 72 (c9orf72) gene contains a hexanucleotide (GGGGCC) repeat expansion responsible for many cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). PMID: 28132891
  44. Psychotic symptoms in frontotemporal dementia with the C9orf72 gene expansion. PMID: 28116236
  45. Intronic repeat expansions in C9orf72 not observed in Iranian Parkinson's disease patients. PMID: 28365006
  46. Its mutation is a genetic cause of amyotrophic lateral sclerosis. PMID: 28222900
  47. Diffuse atrophy is a common underlying feature of disease associated with C9orf72 mutations. PMID: 27995069
  48. Its repeat expansion is a cause of amyotrophic lateral sclerosis in New Zealand. PMID: 27480424
  49. C9orf72 repeat expansions are not causally associated with dementia with lewy body. PMID: 27666590
  50. Repeat expansions in the chromosome 9 open reading frame 72 (C9orf72) gene have been recognized as a major contributor to amyotrophic lateral sclerosis. PMID: 28527524

Show More

Hide All

Involvement in disease
Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 (FTDALS1)
Subcellular Location
Nucleus. Cytoplasm. Cytoplasm, P-body. Cytoplasm, Stress granule. Endosome. Lysosome. Cytoplasmic vesicle, autophagosome. Secreted. Cell projection, axon. Cell projection, growth cone. Perikaryon.; [Isoform 1]: Perikaryon. Cell projection, dendrite.; [Isoform 2]: Nucleus membrane; Peripheral membrane protein. Nucleus.
Tissue Specificity
Both isoforms are widely expressed, including kidney, lung, liver, heart, testis and several brain regions, such as cerebellum. Also expressed in the frontal cortex and in lymphoblasts (at protein level).
Database Links

HGNC: 28337

OMIM: 105550

KEGG: hsa:203228

STRING: 9606.ENSP00000369339

UniGene: Hs.493639

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1